Use of covered stents in simultaneous management of coarctation of the aorta and patent ductus arteriosus
AuthorHekim Yılmaz, Emine
Bulut, Mustafa Orhan
Küçük, Mehmet Alparslan
Yücel, İlker Kemal
MetadataShow full item record
CitationHekim Yılmaz, E., Bulut, M., Küçük, M., Yücel, İ., Erdem, A., ve Çelebi, A. (2018). Use of covered stents in simultaneous management of coarctation of the aorta and patent ductus arteriosus. Anatolian Journal of Cardiology, 19(4), 232-236. https://dx.doi.org/10.14744/AnatolJCardiol.2018.61257
Objective: To report clinical and procedural characteristics of twelve patients who received a covered stent for the treatment of aortic coarctation and concurrent patent ductus arteriosus (PDA). Methods: A single center database was retrospectively evaluated to obtain data of patients with combined aortic coarctation and PDA. We selected patients in whom a covered stent was used for the treatment of both pathologies. The stent length was chosen so as to cover the entire length of the lesion from healthy to healthy tissue and also cover the ampulla of PDA. Results: The median age of the patients was 15 (range, 6.5-35) years. The diameter of the coarctated segment increased from a median of 8.4 (range, 2.6-10.8) mm to 16 (range, 9-24) mm (p<0.005), whereas the pressure gradient decreased from a median of 43 (range, 10-71) mm Hg to 0 (range, 0-8) mm Hg (p<0.005). Fourteen covered stents were used for 12 patients. Following deployment, seven stents were flared with larger and low-pressure balloons because of the gap between the distal end of the stent and the poststenotic dilated segment of the aorta, which caused residual PDA shunts and/or instability of the stent. After the procedure, no residual PDA shunt was present in any patient. Conclusion: To the best of our knowledge, this study includes the largest series of patients reported in literature in whom covered CP stents were used for simultaneous percutaneous treatment of coarctation and PDA. The procedure was successful and stable results were obtained during follow-up in all cases.